You are here: Industry Insights > boehringer

News List

Boehringer Ingelheim announces finalists of the Making More Health Accelerator Program worldpharmanews
May 15, 2019
Boehringer Ingelheim announces finalists of the Making More Health Accelerator Program.
AMAL Therapeutics Enters Clinical Collaboration with Boehringer Ingelheim to Evaluate ATP128 in Combination with BI754091 b3cnewswire
May 05, 2019
AMAL Therapeutics Enters Clinical Collaboration with Boehringer Ingelheim to Evaluate ATP128 in Combination with BI754091.
Boehringer partners PureTech to develop immuno-oncology candidates pharmaceutical-technology
April 24, 2019
Boehringer partners PureTech to develop immuno-oncology candidates.
Diabetes drug sales ease Boehringer's patent-loss pain fiercepharma
April 21, 2019
As sales of its blockbuster asthma and COPD drug Spiriva flagged in 2018, Boehringer Ingelheim needed a boost from its other products. Turns out diabetes was the key.
Boehringer Ingelheim enhances oncology R&D with novel MacroDel delivery technology via acquisition of ICD Therapeutics worldpharmanews
April 10, 2019
Boehringer Ingelheim enhances oncology R&D with novel MacroDel delivery technology via acquisition of ICD Therapeutics...
AbbVie loses bid to hoard documents in Humira patent fight with Boehringer fiercepharma
February 24, 2019
Boehringer Ingelheim is one of the only—if not the only—biosimilar makers still challenging AbbVie’s Humira patents in court. And the German drugmaker just won a skirmish in that high-stakes battle, gaining access to documents AbbVie had fought to keep se
Boehringer inks pact with Domain for GPCR neurology drugs fiercebiotech
January 02, 2019
French-Canadian biotech Domain Therapeutics has another big pharma partner, signing a deal with Germany’s Boehringer Ingelheim to develop new drugs for central nervous system (CNS) disorders....
Boehringer follows Sanofi with job cuts in France pharmaphorum
December 12, 2018
Boehringer Ingelheim has confirmed it plans to axe more than 10% of its workforce in France, or more than 300 jobs, adding to several hundred losses at Sanofi last week.
Boehringer partners with Epizyme to develop new cancer therapies pharmaceutical-technology
November 19, 2018
Boehringer Ingelheim has formed a global alliance with US-based biopharmaceutical firm Epizyme for the research, development and commercialisation of new potential cancer treatments.
Boehringer partners with Epizyme to develop new cancer therapies pharmaceutical-technology
November 19, 2018
Boehringer Ingelheim has formed a global alliance with US-based biopharmaceutical firm Epizyme for the research, development and commercialisation of new potential cancer treatments.

Previous page 1 2 3 4 5 6 Next page